S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
OTCMKTS:AOLS

Aeolus Pharmaceuticals Stock Forecast, Price & News

$0.0032
0.00 (-31.91 %)
(As of 01/15/2021 03:54 PM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.01
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
Volume891,926 shs
Average Volume984,023 shs
Market Capitalization$486,688.00
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

MarketRank

Overall MarketRank

0.75 out of 5 stars

Medical Sector

955th out of 1,480 stocks

Pharmaceutical Preparations Industry

449th out of 612 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AOLS
CUSIPN/A
Phone949-481-9825
Employees4

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$486,688.00
Next Earnings DateN/A
OptionableNot Optionable
$0.0032
0.00 (-31.91 %)
(As of 01/15/2021 03:54 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for AOLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions

How has Aeolus Pharmaceuticals' stock been impacted by COVID-19?

Aeolus Pharmaceuticals' stock was trading at $0.0010 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AOLS stock has increased by 220.0% and is now trading at $0.0032.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Aeolus Pharmaceuticals?

Wall Street analysts have given Aeolus Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aeolus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals, Inc. (OTCMKTS:AOLS) announced its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.01 million during the quarter.
View Aeolus Pharmaceuticals' earnings history
.

Who are some of Aeolus Pharmaceuticals' key competitors?

What other stocks do shareholders of Aeolus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeolus Pharmaceuticals investors own include iBio (IBIO), Myriad Genetics (MYGN), Synergy Pharmaceuticals (SGYP), Titan Pharmaceuticals (TTNP), ADOMANI (ADOM), Agritek (AGTK), Akers Biosciences (AKER), Argos Therapeutics (ARGSQ), Arena Pharmaceuticals (ARNA) and Biohaven Pharmaceutical (BHVN).

Who are Aeolus Pharmaceuticals' key executives?

Aeolus Pharmaceuticals' management team includes the following people:
  • Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 52, Pay $374.02k)
  • Mr. John L. Mcmanus, Chief Exec. Officer and Pres (Age 57, Pay $460.33k)
  • Mr. Christopher Stanley, VP of Operations

What is Aeolus Pharmaceuticals' stock symbol?

Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."

How do I buy shares of Aeolus Pharmaceuticals?

Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aeolus Pharmaceuticals' stock price today?

One share of AOLS stock can currently be purchased for approximately $0.00.

How big of a company is Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals has a market capitalization of $486,688.00. Aeolus Pharmaceuticals employs 4 workers across the globe.

What is Aeolus Pharmaceuticals' official website?

The official website for Aeolus Pharmaceuticals is www.aeoluspharma.com.

How can I contact Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.